-
As the scrutiny and duties of IRBs steadily increase, demanding ever more time from IRB members, it has become clear to some research universities and hospitals that there should be a change in whether and how IRB members are compensated for their time.
-
-
In this issue of IRB Advisor, we are starting a new column designed to answer reader questions. If you have questions regarding IRB responsibilities, federal regulations, adverse event reporting, day- to-day functions, anything related to clarifying the duties and responsibilities of your IRB, wed like to know.
-
Current federal research regulations in the United States limit efforts to study emerging infectious diseases, and an alternative model is needed to allow a rapid response to immediate threats to public safety, a top U.S. researcher claims.
-
In an ideal world, researchers working with mentally ill subjects would be able to present information about their studies in such clear, comprehensive, and organized ways that IRBs could be assured that participants know exactly what to expect.
-
In the summer of 1971, Philip Zimbardo, PhD, was lead investigator on The Stanford Prison Experiment, a study designed to measure the psychological effects that imprisonment and authority would have on participants.
-
-
As experienced physicians understand, heart failure can be a difficult diagnosis to establish in the emergency department setting, especially when there are factors that may complicate a patients presentation. This issue of Emergency Medicine Reports reviews the role and clinical utility of brain natriuretic peptide in the management of patients suspected of having heart failure upon presentation to the ED
-
In the Pipeline
-
Almotriptan malate (Axert) a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, otherwise known as a triptan, was approved by the U.S. Food and Drug Administration (FDA) in May 2001.